Pharma BD Deal Intelligence
2007 · Acquisition/Merger · $150M · Complete
AstraZeneca acquired Arrow Therapeutics for $150 million in cash to add Phase II antiviral programs (RSV604 and HCV NS5A compounds) and a London-based discovery team to its anti-infectives pipeline. The acquisition closed on 2 March 2007.
← Browse all deals · How we score deals